Recursion Pharmaceuticals exceeded EPS expectations by 15.38%. The company reported a significant revenue shortfall, missing forecasts by 60.26%. Pre-market stock price fell 1.84% amid broader biotech ...

Recursion Pharmaceuticals reported its first-quarter 2026 earnings, surpassing EPS expectations but missing revenue forecasts significantly. The company posted an EPS of -$0.22, better than the ...

Abstract: JavaScript has significantly evolved, broadening its capabilities. However, the uptake of tail call optimization (TCO) remains limited, largely due to concerns about debugging difficulties ...

Good morning, everyone, and thank you for joining us. Since stepping into this role, I've been focused on a singular question: how do we harness the full power of AI to consistently and with urgency ...

Look, Recursion has been on an intentional and in many ways a pioneering journey. Early on, Recursion recognized both the immense potential of AI in drug discovery, as well as the reality that unlike ...

EPS exceeded forecasts by 15.38%, reflecting effective cost management. Revenue missed expectations by 60.26%, raising concerns about growth prospects. The stock price fell by 5.34% in pre-market ...

Chris Gibson built the pioneering AI biotech Recursion Pharmaceuticals on a foundation of bold promises. But after more than a decade at the helm, Gibson stepped down as CEO in November 2025. And his ...